LFCR Lifecore Biomedical, Inc.
Price Chart
Executive Summary
Lifecore Biomedical announced a manufacturing services agreement with a leading ophthalmic disease management provider for process development and tech transfer of a next-generation reformulation from vials to pre-filled syringes. This is the sixth late-stage pipeline addition in seven months, but no financial terms or revenue commitments were disclosed.
Actionable Insight
The agreement adds to Lifecore's late-stage pipeline but lacks disclosed financial terms, limiting near-term revenue visibility. Monitor future filings for regulatory approval milestones and potential commercial manufacturing scale-up. The stock may see modest positive sentiment from pipeline growth, but no immediate catalyst is present.
Key Facts
- Agreement covers process development and technical transfer services for an injectable ophthalmic product.
- Program involves transitioning a commercially approved product from vials to pre-filled syringes.
- This is the sixth late-stage pipeline addition in seven months.
- No financial terms, deal value, or revenue guidance were disclosed.
- Commercial manufacturing is contingent upon regulatory approval of the customer's product.
Financial Impact
No financial terms disclosed; revenue potential depends on regulatory approval and future commercial manufacturing volumes.
Risk Factors
- Commercial manufacturing revenue is contingent on customer's regulatory approval, which may be delayed or denied.
- No financial terms disclosed, making it difficult to assess materiality.
- Customer concentration risk if this program represents a significant portion of future revenue.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305014 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
9d ago
|
8-K
| $5.63 awaiting T+1 | awaiting T+1 | — | $5.64 (+0.27%) |
|
Jun 2, 2026
12d ago
|
Press Release
| $5.45 $5.67 | ▲ +4.04% | ▲ +4.73% | $5.64 (+3.49%) |
|
May 6, 2026
5w ago
|
8-K
| $4.96 $4.77 | ▲ +3.83% | ▲ +3.50% | $5.64 (−13.71%) |
|
Mar 26, 2026
11w ago
|
Press Release
| $3.87 $3.66 | ▼ −5.43% | ▼ −3.75% | $5.64 (+45.74%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $4.37 $4.36 | ▼ −0.23% | ▼ −0.50% | $5.64 (+29.06%) |
|
Mar 4, 2026
14w ago
|
Press Release
| $7.02 $6.96 | ▼ −0.85% | ▲ +0.46% | $5.64 (−19.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access